跳至主要内容
临床试验/NCT05796635
NCT05796635已完成不适用

An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores

Focus Consumer Healthcare2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2023年1月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80
试验地点
2
主要终点
The primary aim of this research is to understand the changes in cold sore severity.

研究概览

简要总结

Focus Consumer Healthcare has developed Herpecin L. Herpecin L combines many different ingredients hypothesized to promote quick healing and symptom reduction from cold sores.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Male Female between 18-60 years of age.
  • Must be in good health with no significant chronic conditions and a BMI under
  • Must experience regular cold sores or fever blisters
  • Must agree to avoid daily lip balm or another product designed to alleviate their cold sore (e.g., Abreva or other over-the-counter cold sore products).

排除标准

  • Suffers from pre-existing conditions that would prevent them from adhering to the protocol including chronic conditions such as oncological or psychiatric disorders.
  • Anyone with known severe allergic reactions.
  • Unwilling to follow the study protocol.
  • Currently pregnant, breastfeeding, or wanting to become pregnant for the duration of the study.

结局指标

主要结局

The primary aim of this research is to understand the changes in cold sore severity.

时间窗: 12 weeks

Cold sore severity will be measured via survey and cold sore severity grading. Symptom severity is rated on a scale of 0 (Not a problem) to 6 (Severe)

次要结局

  • The secondary objective of this trial is to examine differences in cold sore frequency between the two groups.(12 weeks)

研究者

发起方
Focus Consumer Healthcare
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验